徐巍
职 称：青年副研究员
电 话：021-54237465
电子邮箱：xuwei11@fudan.edu.cn
办公地点：上海市徐汇区东安路131号复星楼432
个人主页/课题组网页：https://jianglulab.fudan.edu.cn/
教育经历
工作经历
获得奖项
研究方向
科研项目
课程讲授
代表性论著
代表性专利
1999.09—2004.07 北华大学医学检验专业本科生
2004.09—2007.07 北华大学临床检验专业硕士生
2011.09—2014.07 复旦大学病原生物学专业博士研究生
2007.08—2011.07 浙江省台州医院
2014.08—2016.09 上海市疾病预防控制中心
2016.10—2019.10 复旦大学基础医学院博士后
2019.11—至今 复旦大学基础医学院青年副研究员
2013，“一健康”基金，复旦大学上海医学院
生物医药领域，新发与再现病毒感染的病毒融合/进入抑制剂
2018，国家自然科学基金青年项目，“HIV病毒NHR区下游新靶点机制研究”，主持
本科生课程：
医学微生物学本科教学实验课
Xu W#, Cong Z#, Duan Q#, Wang Q, Su S, Wang R, Lu L*, Xue J*, Jiang S*. A protein-based, long-acting HIV-1 fusion inhibitor with an improved pharmacokinetic profile. Pharmaceuticals 2022, 15(4), 424
Duan Q, Xia S, Jiao F, Wang Q, Wang R, Lu L*, Jiang S*, Xu W*. A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life. Viruses 2022, 14(4), 655
Liu Z#, Zhou J#, Xu W#, Deng W#, Wang Y#, Wang M#, Wang Q, Hsieh M, Dong J, Wang X, Huang W, Xing L, He M, Tao C, Xie Y, Zhang Y*, Wang Y*, Zhao J*, Yuan Z*, Qin C*, Jiang S*, Lu L*. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell Res. 2022 Mar;32(3):269-287.
Xu W, Su S, Jiang S. Ring vaccination of COVID-19 vaccines in medium- and high-risk areas of countries with low incidence of SARS-CoV-2 infection. Clin Transl Med. 2021 Feb;11(2):e331.
Xu W, Pu J, Su S, Hua C, Su X, Wang Q, Jiang S*, Lu L*. Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41. AIDS. 2019 Aug 1;33(10):1545-1555.
Xu W#; Pu J #; Su S#; Hua C; Su Xiaojie; Wang Qian; Jiang Shibo*; Lu Lu*; Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41, AIDS, 2019 33(10):1545-1555.
Bi W#, Xu W#, Cheng L, Xue J, Wang Q, Yu F, Xia S, Wang Q, Li G, Qin C, Lu L*, Su L*, Jiang S*. IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. PLoS Pathog. 2019 Dec 5;15(12):e1008082.
Xu W, Xia S, Pu J, Wang Q, Li P, Lu L*, Jiang S*. The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses. Front Microbiol. 2018 Nov 6;9:2643.
Xu W#, Wang Q#, Yu F, Lu L*, Jiang S*. Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs. J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):1-6.
Xu W#, Lu L#, Shen B, Li J, Xu J, Jiang S*. Serological investigation of subclinical influenza A(H7H9) infection among healthcare and non-healthcare workers in Zhejiang Province, China. Clin Infect Dis. 2013 Sep;57(6):919-21
一种抑制艾滋病病毒感染活性的多肽及其相关噬菌体 (已授权：ZL201210379629.2)
一种长效HIV-1膜融合抑制剂 (已授权：ZL201310655778.1)
马来酸卡比沙明在制备抗流感病毒药物中的应用 (已授权：ZL201810996687.7)
一种长效HIV‐1膜融合抑制剂 (已授权：ZL201310655778.1)
